top of page
Press Releases and News
March 25th, 2024 - VUMC team finds potential treatment for kidney fibrosis….. read more
March 3rd, 2024 - Anti-inflammatory control of human skin keratinocytes by targeting nuclear transport checkpoint ….. read more
August 21st, 2023 - Study reveals genomic code for sepsis in the lungs and kidneys ….. read more
July 25th, 2023 - Amytrx Therapeutics' AMTX-100 Phase 1 Clinical Trial Data Presented at Revolutionizing Atopic Dermatitis Conference ….. read more
November 7th, 2022 - A recent study by Vanderbilt investigators with initial support provided by Amytrx Therapeutics demonstrated the molecular control of inflammation in an experimental mouse model of atopic dermatitis (AD) ….. read more
September 1st, 2022 - What’s New in Topicals for Atopic Dermatitis? ….. read more
June 30, 2022 - Amytrx Works with AmbioPharm to Manufacture Its Phase I/II Atopic Dermatitis Asset; August Bioservices, Tergus Pharma Tasked for Topical Formulation... read more
June 9, 2022 - Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis... read more
May 26, 2022 - Two years post-stealth exit, highly secretive inflammation biotech secures final tranche of Series A round... read more
May 25, 2022 - Amytrx Therapeutics Raises $18M for New AD Treatment... read more
October 21, 2021 - Amtryx Therapeutics is featured in Pharma's Almanac 'The Road to 50 States' Interviews... read more
June 8, 2021 - VUMC team develops potential treatment for life-threatening microbial inflammation...read more
October 27, 2020 - Vanderbilt University anti-inflammatory therapy licensed to Amytrx is now in clinical trials for eczema treatment...read more
October 19, 2020 - CEOCFO Magazine Interview with Amytrx CEO About Advancing the Next Generation of Inflammation-Targeting Therapies: AMTX-100 Technology delivers First-in-Class Biologically Active Molecule to Treat Chronic Diseases Mediated by Inflammation...read more
October 8, 2020 - Amytrx Enrolling Clinical Trial of AMTX-100 in Patients with Atopic Dermatitis...read more
September 17, 2020 - Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100 Currently in Clinical Development for Dermatologic Indications....read more
bottom of page